ArticlebioRxiv : the preprint server for biology2025
Cortical α-synuclein pathology induces cell autonomous neuronal hypoactivity and compensatory circuit changes in a model of early Lewy body dementia.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cognitive impairment is a common non-motor symptom of Parkinson's disease (PD) and a defining feature of Dementia with Lewy Bodies (DLB). Although many cognitive domains can be affected, impairments in visuospatial/perceptual function are relatively specific for PD and DLB compared to other dementias. Across populations, cognitive impairments correlate with the presence of α-synuclein (α-syn) pathology in limbic and neocortical brain regions. However, the specific role that α-syn pathology plays in driving cortical circuit dysfunction and cognitive impairment remains controversial. We hypothesized that inducing α-syn pathology in visual cortex in mice would impair neuronal activity and encoding of visual information, leading to visuoperceptual impairments. To test this hypothesis, we injected α-syn pre-formed fibrils (PFF) into primary visual cortex (V1) to seed endogenous α-syn pathology. Using longitudinal in vivo two-photon (2P) calcium imaging over 6 months, we recorded visually evoked activity of pyramidal cells in layer 2/3 (L2/3) and quantified α-syn pathology using C05-05, a fluorescent ligand that binds aggregated α-syn. Injection of PFFs led to the formation of sparse Lewy-like pathology in V1 and other anatomically connected regions. Measuring population activity, we found a greater percentage of neurons in PFF-injected mice were responsive to visual stimuli with lower direction selectivity compared to controls at 4-5 months post-injection (MPI). Within PFF-injected mice, neurons with large somatic Lewy-like inclusions had significantly lower visually evoked activity compared to neighboring neurons without inclusions. Conversely, the activity of neurons without somatic inclusions showed increased activity, positively correlated with the nearby burden of α-syn pathology. Measuring visuoperceptual function using a head-fixed coherent motion discrimination task, we found no impairments in visuoperceptual ability in PFF-injected mice up to 6 MPI. Our results demonstrate, for the first time in vivo, that α-syn pathology leads to cell autonomous reductions in neuronal activity and reciprocal changes in local population activity that may be compensatory, helping to preserve visuoperceptual function. Reflecting the early stages of neocortical α-syn pathology, our model provides a framework for future studies incorporating risk factors for dementia in PD to better understand the heterogeneity of cognitive symptoms and α-syn pathology across patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.